Projects per year
Personal profile
Biography
I am a dedicated and compassionate medical oncologist with a particular interest in genitourinary and
gastrointestinal cancers. I have five years of Consultant Medical Oncology experience, predominantly treating genitourinary and lower gastrointestinal cancers. I have a particularly strong research background, with extensive experience as an investigator in clinical trials and translational research. I have completed a Masters in Clinical Epidemiology and have submitted a PhD in translational prostate cancer. Through working at the NHMRC Clinical Trials Centre and for the ANZUP Trials Group, I have developed trial management experience in large Phase 2 and 3 trials and have established solid research connections and collaborative networks.
Fingerprint
Dive into the research topics where Alison Zhang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
INTerpath-011: CTU: A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Badder Cancer (INTerpath-011)
Zhang, A. (Primary Chief Investigator), Quinlan, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff) & Armstrong, E. (Clinical Trial Unit Staff)
6/03/25 → 15/01/30
Project: Research
-
CTU: A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 in participants with metastatic or unresectable solid tumors with HER2-activating mutations
Zhang, A. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff) & Garcia, M. (Clinical Trial Unit Staff)
10/12/24 → 31/10/29
Project: Research
-
CTU: GO44537 A PHASE I, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7656594 IN PATIENTS WITH ADVANCED OR METASTATIC PROSTATE CANCER
Zhang, A. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff) & McHugh, T. (Clinical Trial Unit Staff)
18/09/24 → 17/08/28
Project: Research
-
MK-5684-01A: CTU: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Zhang, A. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Chester, C. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff) & Martin, L. (Clinical Trial Unit Staff)
12/04/24 → 27/03/29
Project: Research
-
V940-005: CTU: A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Muscle-Invasive Urothelial Carcinoma Post-Radical Resection
Zhang, A. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff) & Chester, C. (Clinical Trial Unit Staff)
12/03/24 → 28/02/29
Project: Research
Research Outputs
- 16 Article
-
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Emmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S.-T., Ng, S., Francis, R. J., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Gedye, C., Rutherford, N. K., Sandhu, S., Kumar, A. R., Pook, D., Ramdave, S. & Nadebaum, D. P. & 20 others, , May 2024, In: The Lancet Oncology. 25, 5, p. 563-571 9 p.Research output: Contribution to journal › Article › peer-review
77 Citations (Scopus) -
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., Francis, R. J., Gedye, C., Rutherford, N. K., Weickhardt, A., Scott, A. M., Lee, S.-T., Kwan, E. M., Azad, A. A. & Ramdave, S. & 12 others, , Jan 2024, In: The Lancet Oncology. 25, 1, p. 99-107 9 p.Research output: Contribution to journal › Article › peer-review
110 Citations (Scopus) -
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Cheung, L., Chi, K. N., Chowdhury, S., Frydenberg, M., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D. & Reaume, N. & 12 others, , Apr 2023, In: The Lancet Oncology. 24, 4, p. 323-334 12 p.Research output: Contribution to journal › Article › peer-review
140 Citations (Scopus) -
Modulation of plasma lipidomic profiles in metastatic castration-resistant prostate cancer by simvastatin
Mak, B., Lin, H.-M., Duong, T., Mahon, K. L., Joshua, A. M., Stockler, M. R., Gurney, H., Parnis, F., Zhang, A., Scheinberg, T., Wittert, G., Butler, L. M., Sullivan, D., Hoy, A. J., Meikle, P. J. & Horvath, L. G., 30 Sept 2022, In: Cancers. 14, 19, p. 1-15 15 p., 4792.Research output: Contribution to journal › Article › peer-review
Open AccessFile8 Citations (Scopus)30 Downloads (Pure) -
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., Azad, A. A., McJannett, M. M., Stockler, M. R., Williams, S. G., Davis, I. D., Hofman, M. S. & TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Nov 2022, In: The Lancet Oncology. 23, 11, p. 1389-1397 9 p.Research output: Contribution to journal › Article › peer-review
168 Citations (Scopus)
Prizes
Activities
- 7 Presentation
-
An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy
Zhang, A. (Speaker)
8 Feb 2018 → 10 Feb 2018Activity: Talk or presentation › Presentation
-
A prospective multi-centre Phase III validation study of AZGP1 as a biomarker in localized prostate cancer
Zhang, A. (Speaker)
13 Feb 2017 → 15 Feb 2017Activity: Talk or presentation › Presentation
-
Chemotherapy reduces time to development of radiation-induced sarcomas
Zhang, A. (Speaker)
2 Jun 2017 → 6 Jun 2017Activity: Talk or presentation › Presentation
-
Toxicity-adjusted dose of sunitinib gives low-intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer
Zhang, A. (Speaker)
30 May 2014 → 3 Jun 2014Activity: Talk or presentation › Presentation
-
Metformin to preventing androgen deprivation therapy-induced insulin resistance and the metabolic syndrome
Zhang, A. (Speaker)
31 Jul 2013 → 2 Aug 2013Activity: Talk or presentation › Presentation